![](https://sdbig.com/wp-content/uploads/2024/03/medium-akEuJF.jpeg)
Novo Nordisk’s blockbuster weight-loss drug cuts the risk of kidney disease-related events in diabetic patients by 24%, according to a new clinical trial conducted by the company.
San Diego Black Investors Group
Novo Nordisk’s blockbuster weight-loss drug cuts the risk of kidney disease-related events in diabetic patients by 24%, according to a new clinical trial conducted by the company.